Title:
|
Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
|
Author:
|
Thaçi, Diamant; Strober, Bruce; Gordon, Kenneth B.; Foley, Peter; Gooderham, Melinda; Morita, Akimichi; Papp, Kim A.; Puig Sanz, Lluís; Menter, M. Alan; Colombo, Matthew J.; Elbez, Yedid; Kisa, Renata M.; Ye, June; Napoli, Andrew A.; Wei, Lan; Banerjee, Subhashis; Merola, Joseph F.; Gottlieb, Alice B.; Universitat Autònoma de Barcelona
|
Abstract:
|
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. Post-hoc analysis of a 12-week Phase 2 trial was conducted for the three most efficacious dosage groups (3 mg twice daily, 6 mg twice daily, 12 mg once daily) and placebo. Investigator assessments for efficacy included Psoriasis Area and Severity Index (PASI), body surface area (BSA) involvement, and static Physician's Global Assessment; QoL was assessed using the Dermatology Life Quality Index (DLQI). Treatment responses and their associations were evaluated over time. Deucravacitinib elicited improvement versus placebo as early as Week 4 for most efficacy measures (including changes in absolute PASI and BSA), with efficacy trends observed from Week 2 to Week 12. Improvements in QoL, assessed by achievement of a DLQI overall score of 0/1 (no effect at all on patient's life), followed a pattern similar to deucravacitinib-related clinical outcomes over 12 weeks. Overall, patients with greater improvements in psoriasis-related clinical signs and symptoms also reported greater improvement in QoL. However, complete skin clearance was not required for achieving DLQI 0/1. Deucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis. Deucravacitinib has the potential to become a promising new oral therapy for this condition. ClinicalTrials.gov identifier; NCT02931838. The online version contains supplementary material available at 10.1007/s13555-021-00649-y. The online version contains supplementary material available at 10.1007/s13555-021-00649-y. |
Subject(s):
|
-Body surface area -Humans -Psoriasis -Quality of life -TYK2 |
Rights:
|
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
https://creativecommons.org/licenses/by-nc/4.0/ |
Document type:
|
Article |
Published by:
|
|
Share:
|
|
Uri:
|
https://ddd.uab.cat/record/256010
|